title: Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.
abstract: Roseoloviruses frequently reactivate in transplant recipients. We review the impact of Roseoloviruses in transplant recipients and highlight research priorities. Human herpesvirus 6A (HHV-6A) and HHV-6B were recently classified as distinct species with important differences. Both viruses can result in inherited chromosomally integrated HHV-6, which may cause complications after transplant. HHV-6B is the primary species associated with disease and appears to have pleiotropic effects on the central nervous system. Small preemptive and prophylactic studies have not shown a statistically significant impact on HHV-6 disease. Although Roseoloviruses are associated with diverse complications in transplant patients, studies providing strong evidence for a causal role are lacking. Trials focusing on prevention and treatment will be important to inform the significance of Roseolovirus reactivation.
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, United States; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. Electronic address: joshuaah@uw.edu.
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Hill
authors.affiliation: Department of Pediatrics, University of Washington, Seattle, WA, United States; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. Electronic address: danielle.zerr@seattlechildrens.org.
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Zerr
mesh_terms: D015654:Herpesvirus 6, Human / Q000235:genetics / Q000502:physiology; D006801:Humans; D016867:Immunocompromised Host; D019349:Roseolovirus Infections / Q000453:epidemiology* / Q000473:pathology*; D066027:Transplant Recipients; D014775:Virus Activation; D016662:Virus Integration